Quantum Biopharma (QNTM) Other Non-Current Liabilities (2020 - 2026)
Quantum Biopharma (QNTM) posted Other Non-Current Liabilities of $6.6 million for Q1 2026, up 357739.62% sequentially from $1835.0 in Q3 2025, and up 129.1% YoY from $2.9 million in Q1 2025.
Quantum Biopharma (QNTM) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Quantum Biopharma has reported Other Non-Current Liabilities for 7 years, with the latest figure at $6.6 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 129.1% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (up 129.1% YoY) and the FY2024 annual result came in at $280000.0, changed N/A from the prior year.
- Other Non-Current Liabilities grew to $6.6 million in Q1 2026 per QNTM's latest filing, from $1835.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $7.8 million in Q2 2025 and troughed at $1.0 in Q2 2024.
- A 5-year average of $1.4 million and a median of $334240.5 in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities tumbled 100.0% in 2024, then soared 776068300.0% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $243594.0 in 2022, then slumped by 46.48% to $130383.0 in 2023, then soared by 114.75% to $280000.0 in 2024, then sank by 99.34% to $1835.0 in 2025, then surged by 357739.62% to $6.6 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $6.6 million, $1835.0, and $7.8 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Quantum Biopharma | 15.44 Mn | 11.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.57 Mn |
| Sep 30, 2025 | 1,835.00 |
| Jun 30, 2025 | 7.76 Mn |
| Mar 31, 2025 | 2.87 Mn |
| Dec 31, 2024 | 280,000.00 |
| Sep 30, 2024 | 75.00 |
| Jun 30, 2024 | 1.00 |
| Sep 30, 2023 | 130,383.00 |
| Jun 30, 2023 | 122,351.00 |
| Mar 31, 2023 | 450,544.00 |
| Dec 31, 2022 | 243,594.00 |
| Sep 30, 2022 | 388,481.00 |
| Jun 30, 2022 | 425,620.00 |
| Mar 31, 2022 | 522,884.00 |
| Dec 31, 2021 | 765,403.00 |
| Sep 30, 2021 | 1.43 Mn |
| Jun 30, 2021 | 1.71 Mn |
| Mar 31, 2021 | 2.00 Mn |
| Dec 31, 2020 | 1.45 Mn |
| Sep 30, 2020 | 2.61 Mn |